When I first heard Figma was going public, I got a little jolt of excitement. I’ve followed their journey since the Adobe acquisition news fell through. Now, with a rumored $16.5 billion valuation and a fresh IPO on the horizon, it feels like we’re watching something huge unfold. But there’s a lot to unpack—financials, risks, the tech space, and whether this stock is really worth your attention. Figma’s IPO comes at a time when tech IPOs are rare and scrutiny is sky-high. And if you’re like me, you’ve seen one too many startups overpromise and underdeliver. So, how does Figma…
Author: Thomas
I’ve had Kohl’s (NYSE: KSS) stock on my radar for years. As someone who follows retail closely and likes to look for value in beaten-down names, KSS is one of those stocks that pulls me back in every few months. Some days it looks like a hidden gem. Other days, it feels like a dividend trap waiting to snap shut. If you’ve been eyeing it like I have, you’re probably wondering: is it finally worth a deeper look? We’ve seen some wild moves lately in KSS stock, including a 37% surge in a single day, followed by a brutal 14%…
Have you ever wondered why a stock starts the day at one price but ends at another? When I first started trading, I was obsessed with the price at market open. It felt like a signal — a pulse check — on the entire day ahead. I didn’t realize then how much the opening stock price could tell me about market sentiment, volatility, or even trader psychology. But here’s the thing: most new traders either ignore it or misunderstand it. They chase after headlines or rely on closing prices without realizing the market often shows its hand the moment it…
Some days, you just feel the pulse of the market racing. Today was one of those days. I was glued to my screen during pre-market hours, watching Garden Stage Limited (GSIW) light up the ticker with a massive 66% spike. It’s that electric moment every trader lives for—spotting a rocket before it takes off. But the problem? If you’re not tracking these moves daily, you’ll miss out. I’ve missed plenty myself. I remember watching American Eagle Outfitters surge and realizing too late it had popped over 20% because of a surprise earnings beat. That’s when I committed to building a…
I remember the first time I heard the term “block stock” — I thought it had something to do with supply chain or logistics. Turns out, it’s a key concept in financial markets. The problem is, most people, especially new traders, get confused by it. That’s understandable. It’s not something you pick up just by watching the ticker. So, what is block stock? And why should you care? If you’ve ever wondered why some trades never seem to move the market despite being huge, or why certain price moves happen out of nowhere, you might be seeing the effects of…
I still remember the first time I earned crypto. It wasn’t through trading, mining, or investing. I simply downloaded a browser extension that rewarded me in Bitcoin for browsing the web. I wasn’t even sure it would work, but it did. And just like that, my journey into the world of earning cryptocurrency began—with zero upfront cost and a whole lot of curiosity. Most people still think you need thousands of dollars or a degree in blockchain to get started with crypto. Truth is, you don’t. What you need is the right knowledge, a bit of patience, and the willingness…
I’ve been watching Sarepta Therapeutics for months now. And let me tell you, what just happened to this stock hit like a freight train. The drop in SRPT wasn’t just a dip. It was a full-on freefall that left investors scrambling for answers. If you’ve ever held a biotech stock, you know it’s not for the faint of heart. But Sarepta’s collapse? That’s another level. So, what triggered this crash? Why are analysts bailing? And most importantly — should you stay or run? That’s exactly what I’ll unpack here. You’re getting the full story from someone who’s been neck-deep in…
If you’re like me, you’ve probably glanced at Elevance Health’s stock chart and wondered — is this quiet giant actually undervalued? With all the noise in the healthcare sector, sometimes it’s tough to see the signals through the static. Here’s the issue. ELV, trading at $296.60 with a low P/E ratio of 12.65, looks like a bargain — but it’s down roughly 44% from its 52-week high. Add in lawsuits and rising medical costs, and it’s no surprise folks are cautious. I was too. So, I decided to dig deep. In this guide, I’ll walk you through: What Elevance Health…
I’ve been in the crypto space for years, and I’ll admit—it took me way too long to find a tool that actually made it easy to compare coins side by side. Most platforms either gave me too much fluff or not enough data. That changed when I found CryptoCompare. Here’s the thing: tracking crypto prices is only half the battle. If you don’t understand volume, market cap, or algorithm differences, you’re missing the full picture. And if you’re a developer building crypto tools, you need reliable APIs and clean data. That’s where CryptoCompare shines. In this guide, I’ll walk you…
Ever feel like you’re late to the trade? That used to be me, especially when it came to sector ETFs like healthcare. Then I discovered CURE—and I learned fast that this isn’t your typical stock. It’s an adrenaline-packed, 3x leveraged ETF that amplifies daily healthcare moves. Sounds exciting, right? It is. But it’s not for everyone. Many traders fall into the trap of thinking CURE is just another healthcare ETF. I did, too—until I watched my positions swing wildly because I didn’t understand how daily leverage and compounding worked. That mistake cost me. So I want to break this down…